Assessment of the viral safety of antivenoms fractionated from equine plasma

Biologicals

Volumn 32, Issue 3, 2004, Pages 115-128

  Burnouf, Thierry ^a   Griffiths, Elwyn ^b   Padilla, Ana ^c   Seddik, Salwa ^d   Stephano, Marco Antonio ^e   Gutiérrez, José María ^f  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b HEALTH CANADA   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Drugs 51 Wezaret El Zeraa St G   (Egypt)

^e INSTITUTO BUTANTAN   (Brazil)

^f UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; OCTANOIC ACID; VENOM ANTISERUM;

BORNA DISEASE VIRUS; CHROMATOGRAPHY; CORONAVIRUS; DRUG MANUFACTURE; DRUG SAFETY; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; EQUINE HERPES VIRUS; EQUINE INFECTIOUS ANEMIA VIRUS; EQUINE VIRAL ARTERITIS VIRUS; FRACTIONATION; HEAT TREATMENT; HENDRA VIRUS; HORSE; HUMAN; INFLUENZA VIRUS; JAPANESE ENCEPHALITIS VIRUS; MONITORING; NIPAH VIRUS; NONHUMAN; PH; PICORNAVIRUS; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; REOVIRUS; ROTAVIRUS; SHORT SURVEY; SPUMA VIRUS; ST LOUIS FLAVIVIRUS; STORAGE; VALIDATION PROCESS; VESICULAR STOMATITIS VIRUS; VIRAL CONTAMINATION; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALIA; ARANEAE; EQUIDAE; OVIS ARIES; SCORPIONES; SERPENTES;

EID: 7944238860     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2004.07.001     Document Type: Review

References (111)

1. D.G. Lalloo, and R.D. Theakston Snake antivenoms J Toxicol Clin Toxicol 41 2003 277 290 317-27
2. B.J. Currie Marine antivenoms J Toxicol Clin Toxicol 41 2003 301 308
3. D.A. Warrell, and P.J. Fenner Venomous bites and stings Br Med Bull 49 1993 423 439
4. G.D. Laing, J.M. Renjifo, F. Ruiz, R.A. Harrison, A. Nasidi, and J.M. Gutierrez A new Pan African polyspecific antivenom developed in response to the antivenom crisis in Africa Toxicon 42 2003 35 41
5. R.D. Theakston, D.A. Warrell, and E. Griffiths Report of a WHO workshop on the standardization and control of antivenoms Toxicon 41 2003 541 557
6. J.P. Chippaux, and M. Goyffon Venoms, antivenoms and immunotherapy Toxicon 36 1998 823 846
7. R.C. Dart, and J. McNally Efficacy, safety, and use of snake antivenoms in the United States Ann Emerg Med 37 2001 181 188
8. R.D. Theakston, and D.A. Warrell Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings Toxicon 29 1991 1419 1470
9. D.A. Warrell Clinical toxicology of snakebite in Asia J. Meier J. White Handbook of clinical toxicology of animal venoms and poisons 1995 CRC Press Boca Raton, Florida 493 594
10. J.P. Chippaux Snake-bites: appraisal of the global situation Bull World Health Organ 76 1998 515 524
11. J.M. Gutiérrez Clinical toxicology of snakebite in Central America J. Meier J. White Handbook of toxicology of animal venoms and poisons 1995 CRC Press Boca Raton, Florida 645 665
12. M. Dehesa-Dávila, A. Alagón, and L. Possani Clinical toxicology of scorpion stings J. Meier J. White Handbook of clinical toxicology of animal venoms and poisons 1995 CRC Press Boca Raton, Florida 221 238
13. S.S. Seddik, S. Wanas, A. Shehata, S. Fawaz, and M.H. Helmy Development of an improved method for production of antiscorpion F(ab′)2 fragment of IgG with high yield and potency J Nat Toxins 11 2002 123 132
14. G.K. Isbister, A. Graudins, J. White, and D. Warrell Antivenom treatment in arachnidism J Toxicol Clin Toxicol 41 2003 291 300
15. A. Ivan, and L.L. Indrei Emergence of transmissible disorders, a continuous process - a new type of viral meningoencephalitis Rev Med Chir Soc Med Nat Iasi 104 2000 51 55
16. O.R. Kaaden, W. Eichhorn, and S. Essbauer Recent developments in the epidemiology of virus diseases J Vet Med B Infect Dis Vet Public Health 49 2002 3 6
17. S.K. Ng Possible role of an animal vector in the SARS outbreak at Amoy Gardens Lancet 362 2003 570 572
18. A. Abbott, and D. Cyranoski Biologists seek to head off future sources of infection Nature 423 2003 3
19. Note for guidance on production and quality control of animal immunoglobulins and immunsera for human use 2002 European Agency for the Evaluation of Medicinal Products (EMEA) London p. 1-14
20. I.H. Barrette-Ng, K.K. Ng, B.L. Mark, D. Van Aken, M.M. Cherney, and C. Garen Structure of arterivirus nsp4. The smallest chymotrypsin-like proteinase with an alpha/beta C-terminal extension and alternate conformations of the oxyanion hole J Biol Chem 277 2002 39960 39966
21. B.D. Moore, U.B. Balasuriya, J.F. Hedges, and N.J. MacLachlan Growth characteristics of a highly virulent, a moderately virulent, and an avirulent strain of equine arteritis virus in primary equine endothelial cells are predictive of their virulence to horses Virology 298 2002 39 44
22. U.B. Balasuriya, C.M. Leutenegger, J.B. Topol, W.H. McCollum, P.J. Timoney, and N.J. MacLachlan Detection of equine arteritis virus by real-time TaqMan reverse transcription-PCR assay J Virol Methods 101 2002 21 28
23. M. Giese, U. Bahr, N.J. Jakob, R. Kehm, M. Handermann, and H. Muller Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus Virus Genes 25 2002 159 167
24. G. Dauphin, V. Legay, P.H. Pitel, and S. Zientara Borna disease: current knowledge and virus detection in France Vet Res 33 2002 127 138
25. K. Ikuta, M.S. Ibrahim, T. Kobayashi, and K. Tomonaga Borna disease virus and infection in humans Front Biosci 7 2002 d470 d495
26. H. Ludwig, and L. Bode Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology Rev Sci Tech 19 2000 259 288
27. F. Del Piero, P.A. Wilkins, E.J. Dubovi, B. Biolatti, and C. Cantile Clinical, pathologic, immunohistochemical, and virologic findings of eastern equine encephalomyelitis in two horses Vet Pathol 38 2001 451 456
28. A.J. Lambert, D.A. Martin, and R.S. Lanciotti Detection of North American eastern and western equine encephalitis viruses by nucleic acid amplification assays J Clin Microbiol 41 2003 379 385
29. M.M. Jochim, and T.L. Barber Immune response of horses after simultaneous or sequential vaccination against eastern, western, and Venezuelan equine encephalomyelitis J Am Vet Med Assoc 165 1974 621 625
30. R.P. Franklin, H. Kinde, M.T. Jay, L.D. Kramer, E.G. Green, and R.E. Chiles Eastern equine encephalomyelitis virus infection in a horse from California Emerg Infect Dis 8 2002 283 288
31. J.S. Guy, J.J. Breslin, B. Breuhaus, S. Vivrette, and L.G. Smith Characterization of a coronavirus isolated from a diarrheic foal J Clin Microbiol 38 2000 4523 4526
32. C.H. Lecellier, M. Neves, M.L. Giron, J. Tobaly-Tapiero, and A. Saib Further characterization of equine foamy virus reveals unusual features among the foamy viruses J Virol 76 2002 7220 7227
33. S. Taouji, C. Collobert, B. Gicquel, C. Sailleau, N. Brisseau, and C. Moussu Detection and isolation of equine herpesviruses 1 and 4 from horses in Normandy: an autopsy study of tissue distribution in relation to vaccination status J Vet Med B Infect Dis Vet Public Health 49 2002 394 399
34. C. van Maanen Equine herpesvirus 1 and 4 infections: an update Vet Q 24 2002 58 78
35. O. Kershaw, T. von Oppen, F. Glitz, E. Deegen, H. Ludwig, and K. Borchers Detection of equine herpesvirus type 2 (EHV-2) in horses with keratoconjunctivitis Virus Res 80 2001 93 99
36. A. Nordengrahn, M. Merza, C. Ros, A. Lindholmc, V. Palfl, and D. Hannant Prevalence of equine herpesvirus types 2 and 5 in horse populations by using type-specific PCR assays Vet Res 33 2002 251 259
37. R.F. Cook, S.J. Cook, F.L. Li, R.C. Montelaro, and C.J. Issel Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV) J Virol Methods 105 2002 171 179
38. C. van Maanen, and A. Cullinane Equine influenza virus infections: an update Vet Q 24 2002 79 94
39. L.F. Wang, M. Yu, E. Hansson, L.I. Pritchard, B. Shiell, and W.P. Michalski The exceptionally large genome of Hendra virus: support for creation of a new genus within the family Paramyxoviridae J Virol 74 2000 9972 9979
40. K. Halpin, P.L. Young, H. Field, and J.S. Mackenzie Newly discovered viruses of flying foxes Vet Microbiol 68 1999 83 87
41. M.M. Williamson, P.T. Hooper, P.W. Selleck, L.J. Gleeson, P.W. Daniels, and H.A. Westbury Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats Aust Vet J 76 1998 813 818
42. P.T. Hooper, and M.M. Williamson Hendra and Nipah virus infections Vet Clin North Am Equine Pract 16 2000 597 603
43. S.C. Barker The Australian paralysis tick may be the missing link in the transmission of Hendra virus from bats to horses to humans Med Hypotheses 60 2003 481 483
44. L.A. Selvey, R.M. Wells, J.G. McCormack, A.J. Ansford, K. Murray, and R.J. Rogers Infection of humans and horses by a newly described morbillivirus Med J Aust 162 1995 642 645
45. H.A. Westbury Hendra virus disease in horses Rev Sci Tech 19 2000 151 159
46. A.J. Barclay, and D.J. Paton Hendra (equine morbillivirus) Vet J 160 2000 169 176
47. I.L. Smith, K. Halpin, D. Warrilow, and G.A. Smith Development of a fluorogenic RT-PCR assay (TaqMan) for the detection of Hendra virus J Virol Methods 98 2001 33 40
48. H. Nakamura Japanese encephalitis in horses in Japan Equine Vet J 4 1972 155 156
49. K. Chong Sue, C. Teoh Kim, N.J. Marchette, R. Garcia, A. Rudnick, and R.F. Coughlan Japanese B encephalitis in a horse Aust Vet J 44 1968 23 25
50. R.W. Renshaw, A.L. Glaser, H. Van Campen, F. Weiland, and E.J. Dubovi Identification and phylogenetic comparison of Salem virus, a novel paramyxovirus of horses Virology 270 2000 417 429
51. A.L. Glaser, R.W. Renshaw, S.C. Trock, R.C. Brady, and E.J. Dubovi Isolation of Salem virus, a novel equine paramyxovirus, and assessment of its etiologic role in a disease outbreak Vet Microbiol 87 2002 205 212
52. B.J. McCluskey, and E.L. Mumford Vesicular stomatitis and other vesicular, erosive, and ulcerative diseases of horses Vet Clin North Am Equine Pract 16 2000 457 469
53. E.M. Zhou, J. Riva, and A. Clavijo Development of an immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay for detection of equine and swine IgM antibodies to vesicular stomatitis virus Clin Diagn Lab Immunol 8 2001 475 481
54. R.G. McLean, S.R. Ubico, D. Bourne, and N. Komar West Nile virus in livestock and wildlife Curr Top Microbiol Immunol 267 2002 271 308
55. M.L. Bunning, R.A. Bowen, C.B. Cropp, K.G. Sullivan, B.S. Davis, and N. Komar Experimental infection of horses with West Nile virus Emerg Infect Dis 8 2002 380 386
56. M.B. Porter, M.T. Long, L.M. Getman, S. Giguere, R.J. MacKay, and G.D. Lester West Nile virus encephalomyelitis in horses: 46 cases (2001) J Am Vet Med Assoc 222 2003 1241 1247
57. C.A. Hartley, N. Ficorilli, K. Dynon, H.E. Drummer, J.A. Huang, and M.J. Studdert Equine rhinitis A virus: structural proteins and immune response J Gen Virol 82 2001 1725 1728
58. J.A. Huang, N. Ficorilli, C.A. Hartley, R.S. Wilcox, M. Weiss, and M.J. Studdert Equine rhinitis B virus: a new serotype J Gen Virol 82 2001 2641 2645
59. P.G. Howell, D. Groenewald, C.W. Visage, A.M. Bosman, J.A. Coetzer, and A.J. Guthrie The classification of seven serotypes of equine encephalosis virus and the prevalence of homologous antibody in horses in South Africa Onderstepoort J Vet Res 69 2002 79 93
60. M. Elschner, J. Prudlo, H. Hotzel, P. Otto, and K. Sachse Nested reverse transcriptase-polymerase chain reaction for the detection of group A rotaviruses J Vet Med B Infect Dis Vet Public Health 49 2002 77 81
61. C. Pope The action of proteolytic enzymes on the antitoxins and proteins in immune sera. I. True digestion of the proteins Br J Exp Pathol 20 1939 132
62. C. Pope The action of proteolytic enzymes on the antitoxins and proteins in immune sera. II. Heat denaturation after partial enzyme action Br J Exp Pathol 20 1939 201 212
63. A. Harms The purification of antitoxic plasmas by enzyme treatment and heat denaturation Biochem J 42 1948 390 397
64. I. Raw, R. Guidolin, H.G. Higashi, and E.M.A. Kelen Antivenins in Brazil: preparation A.T. Tu Handbook of natural toxins. Reptile venoms and toxins 1991 Marcel Dekker New York 557 581
65. S.S. Jadhav, and S.V. Kapre Antivenin production in India A.T. Tu Reptile venoms and toxins Handbook of natural toxions vol. 5 1991 Marcel Dekker New York 583 610
66. M. Grandgeorge, J.L. Véron, C. Lutsch, M.F. Makula, P. Riffard, and S. Pépin Preparation of improved F(ab′)2 antivenoms. An example: new polyvalent European viper antivenom (equine) C. Bon M. Goyffon Envenomings and their treatments 1996 Fondation Marcel Mérieux Lyon 161 172
67. R.G. Jones, and J. Landon A protocol for 'enhanced pepsin digestion': a step by step method for obtaining pure antibody fragments in high yield from serum J Immunol Methods 275 2003 239 250
68. T. Saetang, N. Treamwattana, P. Suttijitpaisal, and K. Ratanabanangkoon Quantitative comparison on the refinement of horse antivenom by salt fractionation and ion-exchange chromatography J Chromatogr B Biomed Sci Appl 700 1997 233 239
69. R. Bolaños Antivenenos Manual de Procedimientos. Producción y Pruebas de Control en la Preparación de Antisueros Diftérico, Tetánico, Botulínico, Antivenenos y de la Gangrena Gaseosa 1977 Organización Panamericana de la Salud Washington, DC p. 104-41
70. M.C. dos Santos, M.R. D'Imperio Lima, G.C. Furtado, G.M. Colletto, T.L. Kipnis, and W. Dias da Silva Purification of F(ab′)2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield Toxicon 27 1989 297 303
71. R. Otero, J.M. Gutiérrez, G. Rojas, V. Nuñez, A. Diaz, and M.F. Toro A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms Toxicon 37 1999 895 908
72. G. Rojas, J.M. Jiménez, and J.M. Gutiérrez Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production Toxicon 32 1994 351 363
73. S. Rawat, G. Laing, D.C. Smith, D. Theakston, and J. Landon A new antivenom to treat eastern coral snake (Micrurus fulvius fulvius) envenoming Toxicon 32 1994 185 190
74. C. Karlson-Stiber, H. Persson, A. Heath, D. Smith, I.H. al-Abdulla, and L. Sjostrom First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming J Intern Med 241 1997 53 58
75. W.P. Meyer, A.G. Habib, A.A. Onayade, A. Yakubu, D.C. Smith, and A. Nasidi First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom Am J Trop Med Hyg 56 1997 291 300
76. R. Guidolin, J.F. Morais, M.A. Stephano, J.R. Marcelino, I.K. Yamaguchi, and H.G. Higashi Effect of beta-propiolactone treatment on the complement activation mediated by equine antisera Rev Inst Med Trop Sao Paulo 39 1997 119 122
77. J.M. Gutiérrez, G. Leon, and B. Lomonte Pharmacokinetic- pharmacodynamic relationships of immunoglobulin therapy for envenomation Clin Pharmacokinet 42 2003 721 741
78. G. Rojas, M. Espinoza, B. Lomonte, and J.M. Gutiérrez Effect of storage temperature on the stability of the liquid polyvalent antivenom produced in Costa Rica Toxicon 28 1990 101 105
79. M. Garcia, M. Monge, G. Leon, S. Lizano, E. Segura, and G. Solano Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation Biologicals 30 2002 143 151
80. T. Burnouf, and M. Radosevich Reducing the risk of infection from plasma products: specific preventative strategies Blood Rev 14 2000 94 110
81. W. Nicklas, P. Baneux, R. Boot, T. Decelle, and A.A. Deeny Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units Lab Anim 36 2002 20 42
82. C. Rehbinder, S. Alenius, J. Bures, M.L. de las Heras, C. Greko, and P.S. Kroon FELASA recommendations for the health monitoring of experimental units of calves, sheep and goats Report of the federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health Lab Anim 34 2000 329 350
83. C. Rehbinder, P. Baneux, D. Forbes, H. van Herck, W. Nicklas, and Z. Rugaya FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995 Lab Anim 30 1996 193 208
84. T. Burnouf Chromatography in plasma fractionation: benefits and future trends J Chromatogr B Biomed Appl 664 1995 3 15
85. B. Horowitz, M.P. Piet, A.M. Prince, C.A. Edwards, A. Lippin, and L.A. Walakovits Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids Vox Sang 54 1988 14 20
86. J.L. Lundblad, and R.L. Seng Inactivation of lipid-enveloped viruses in proteins by caprylate Vox Sang 60 1991 75 81
87. H. Dichtelmuller, D. Rudnick, and M. Kloft Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution Biologicals 30 2002 135 142
88. M. Korneyeva, J. Hotta, W. Lebing, R.S. Rosenthal, L. Franks, and S.R. Petteway Jr. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates Biologicals 30 2002 153 162
89. A. Johnston, E. Uren, D. Johnstone, and J. Wu Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies Biologicals 31 2003 213 221
90. K.G. Reid, B. Cuthbertson, A.D. Jones, and R.V. McIntosh Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products Vox Sang 55 1988 75 80
91. P.L. Yap The viral safety of intravenous immune globulin Clin Exp Immunol 104 Suppl. 1 1996 35 42
92. O.J. Bos, D.G. Sunye, C.E. Nieuweboer, F.A. van Engelenburg, H. Schuitemaker, and J. Over Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process Biologicals 26 1998 267 276
93. A. Omar, C. Kempf, A. Immelmann, M. Rentsch, and J.J. Morgenthaler Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation Transfusion 36 1996 866 872
94. E. Hamalainen, H. Suomela, and P. Ukkonen Virus inactivation during intravenous immunoglobulin production Vox Sang 63 1992 6 11
95. M. Burnouf-Radosevich Viral safety of intravenous immunoglobulins G for therapeutic use Transfus Clin Biol 2 1995 167 179
96. N. Heimburger, and H.E. Karges Strategies to produce virus-safe blood derivatives Curr Stud Hematol Blood Transfus 1989 23 33
97. B. Horowitz, M.E. Wiebe, A. Lippin, J. Vandersande, and M.H. Stryker Inactivation of viruses in labile blood derivatives. II. Physical methods Transfusion 25 1985 523 527
98. J. Hilfenhaus, and E. Weidmann Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates Arzneimittelforschung 36 1986 621 625
99. T. Nowak, M. Niedrig, D. Bernhardt, and J. Hilfenhaus Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation Dev Biol Stand 81 1993 169 176
100. M. Burnouf-Radosevich, T. Burnouf, and J.J. Huart A pasteurized therapeutic plasma Infusionsther Transfusionsmed 19 1992 91 94
101. P.K. Ng, and M.B. Dobkin Pasteurization of antihemophilic factor and model virus inactivation studies Thromb Res 39 1985 439 447
102. H.A. Goubran, T. Burnouf, and M. Radosevich Virucidal heat-treatment of single plasma units: a potential approach for developing countries Haemophilia 6 2000 597 604
103. T.R. Kreil, A. Berting, O. Kistner, and J. Kindermann West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data Transfusion 43 2003 1023 1028
104. T. Burnouf, and M. Radosevich Affinity chromatography in the industrial purification of plasma proteins for therapeutic use J Biochem Biophys Methods 49 2001 575 586
105. T. Burnouf Chromatographic removal of viruses from plasma derivatives Dev Biol Stand 81 1993 199 209
106. R. Nisini, S. Le Moli, P.M. Matricardi, A. Fattorossi, and R. D'Amelio A comparative in vitro study of low pH and enzyme treated immunoglobulin preparation for intravenous use J Clin Lab Immunol 29 1989 193 197
107. R.E. Louie, C.J. Galloway, M.L. Dumas, M.F. Wong, and G. Mitra Inactivation of hepatitis C virus in low pH intravenous immunoglobulin Biologicals 22 1994 13 19
108. I. Al-Abdulla, J.M. Garnvwa, S. Rawat, D.S. Smith, J. Landon, and A. Nasidi Formulation of a liquid ovine Fab-based antivenom for the treatment of envenomation by the Nigerian carpet viper (Echis ocellatus) Toxicon 42 2003 399 404
109. World Health Organization Expert Committee of Biological Standardization Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products www.who.int/Biologicals-Quality Assurance and Safety 2003 p. 1-72
110. T. Burnouf, and M. Radosevich Nanofiltration of plasma-derived biopharmaceutical products Haemophilia 9 2003 24 37
111. A. Lazar, E. Epstein, S. Lustig, A. Barnea, L. Silberstein, and S. Reuveny Inactivation of West-Nile virus during peptic cleavage of horse plasma IgG Biologicals 30 2002 163 165